DIGITIMES

OpenAI acquires Orchestra Bio to advance AI drug development

OpenAI has acquired biotech startup Orchestra Bio and will integrate its team and technology into its life sciences research platform, Rosalind, expanding AI applications in drug development in an effort to accelerate the arrival of new therapies.

By DIGITIMES

1 min read
OpenAI acquires Orchestra Bio to advance AI drug development
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Semiconductors & Microelectronics

Related Insights